Related Experiment Videos

Somatostatin analogue in short term management of hyperinsulinism

J M Kirk1, L Di Silvio, P C Hindmarsh

  • 1Endocrine Unit, Middlesex Hospital, London.

Archives of Disease in Childhood
|December 1, 1988
PubMed

Insights

A somatostatin analogue effectively managed hyperinsulinism-induced hypoglycemia in infants. This treatment raised blood glucose levels and reduced glucose needs, showing promise for short-term infant care.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Neonatal Care

Background:

  • Hyperinsulinism is a critical condition in infants causing severe hypoglycemia.
  • Managing persistent hypoglycemia in neonates presents significant clinical challenges.

Purpose of the Study:

  • To evaluate the efficacy of a somatostatin analogue in treating infantile hyperinsulinism-induced hypoglycemia.
  • To assess the impact of somatostatin analogue on blood glucose levels and glucose requirements in affected infants.

Main Methods:

  • Treatment of five infants with hyperinsulinism-related hypoglycemia using a somatostatin analogue.
  • Monitoring of blood glucose concentration and daily glucose requirements during the treatment period (3-11 days).

Main Results:

  • All five infants demonstrated an increase in mean blood glucose concentration.
  • All treated infants showed a reduction in their overall glucose requirements.
  • The somatostatin analogue was well-tolerated during the short-term treatment period.

Conclusions:

  • Somatostatin analogue therapy is a viable option for the short-term management of hyperinsulinism-induced hypoglycemia in infants.
  • This therapeutic approach offers a potential strategy to stabilize glucose levels and decrease dependency on intravenous glucose support.

Related Concept Videos